Skip to main content
Quest Diagnostics

Humoral and Cellular Immune Responses Against SARS-CoV-2 Post-vaccination in Immunocompetent and Immunocompromised Cancer Populations

Humoral and Cellular Immune Responses Against SARS-CoV-2 Post-vaccination in Immunocompetent and Immunocompromised Cancer Populations

Authors: Titova E, Kan VW, Lozy T, Ip A, Shier K, Prakash VP, Starolis M, Ansari S, Goldgirsh K, Kim S, Pelliccia MC, Mccutchen A, Megalla M, Gunning TS, Kaufman HW, Meyer WA 3rd, Perlin DS

Citation: Microbiol Spectr. 2024 Feb 14:e0205023. doi: 10.1128/spectrum.02050-23. Online ahead of print.

Specialties: Infectious disease, COVID-19, Oncology, Immunology, 

Related content

Publication
New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Test FAQ
SARS CoV 2 Antibody Testing
Audio Podcast
Optimize Oncology Care with Clinical Pathways

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.